Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene has closed its acquisition of Gloucester Pharmaceuticals (Gloucester) following the early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Subscribe to our email newsletter
Celgene has acquired Gloucester for $340m in cash plus up to an additional $300m payable upon achievement of certain future regulatory milestones.
The transaction brings to Celgene Istodax (romidepsin), an approved therapy for the treatment of cutaneous T-cell lymphoma (CTCL), providing a strategic fit and expanding the company’s presence in critical blood cancers.
Sol Barer, chairman and CEO of Celgene, said: “There is a need for better treatment options for CTCL patients and this acquisition enables Celgene to maximise the clinical and commercial potential of Istodax through our existing infrastructure, to the benefit of patients. Istodax now joins Revlimid, Vidaza and Thalomid in a robust portfolio of products for the treatment of blood cancers.”